Suspension of loteprednol etabonate for ear, eye, or nose treatment
First Claim
Patent Images
1. A composition for ophthalmic or otolaryngological anti-inflammatory use comprising:
- (A) a corticosteroid having a particle size of 0.1 to 30 microns in diameter in an amount of about 0.2 to 2% by weight;
(B) a nonionic polymer in an aqueous medium;
(C) a nonionic surface active agent in an amount sufficient to retain the corticosteroid in suspension; and
(D) a nonionic tonicity agent in an amount sufficient to achieve isotonicity, wherein the molar ratio of (A);
(B);
(C) is between about 1;
20;
1 and about 1;
0.01;
0.5.
10 Assignments
0 Petitions
Accused Products
Abstract
The invention provides novel compositions of matter containing water-insoluble steroid drugs suitable for therapeutic use. The invention provides stable aqueous suspensions of water-insoluble steroid drugs of particle sizes of ≦15 μm which remain in such a state so as to allow for immediate suspension, when desired, even after extended periods of settling.
109 Citations
17 Claims
-
1. A composition for ophthalmic or otolaryngological anti-inflammatory use comprising:
-
(A) a corticosteroid having a particle size of 0.1 to 30 microns in diameter in an amount of about 0.2 to 2% by weight; (B) a nonionic polymer in an aqueous medium; (C) a nonionic surface active agent in an amount sufficient to retain the corticosteroid in suspension; and (D) a nonionic tonicity agent in an amount sufficient to achieve isotonicity, wherein the molar ratio of (A);
(B);
(C) is between about 1;
20;
1 and about 1;
0.01;
0.5. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
-
-
13. A composition for ophthalmic or otolaryngological anti-inflammatory use comprising a nonionic polymer in an aqueous medium, a nonionic tonicity agent in an amount effective to product isotonicity, and a nonionic surface active agent in an amount sufficient to retain the polymer and tonicity agent in the aqueous medium, and further comprising a corticosteroid having a particle size of 0.1 to 30 microns in diameter in an amount of about 0.2 to 2% by weight, wherein the molar ratio of corticosteroid to nonionic polymer to nonionic surface active agent is between about 1:
- 20;
1 and about 1;
0.01;
0.05. - View Dependent Claims (14, 15, 16, 17)
- 20;
Specification